The effects of neridronate (an intravenous N-bisphosphonate with high skeletal affinity) have been investigated in terms of disease activity in an open-label study vs infliximab (a TNF inhibitor approved for the treatment of SpA) in patients affected by ankylosing spondylitis (AS) [124]. The gene discussed is TNF; the disease is ankylosing spondylitis.